Renal cell carcinoma: The search for a reliable biomarker

Nicholas J. Farber, Christopher J. Kim, Parth K. Modi, Jane D. Hon, Evita T. Sadimin, Eric Singer

Research output: Contribution to journalReview article

23 Scopus citations


One particular challenge in the treatment of kidney tumors is the range of histologies and tumor phenotypes a renal mass can represent. A kidney tumor can range from benign (e.g., oncocytoma) to a clinically indolent malignancy (e.g., papillary type I, chromophobe) to aggressive disease [e.g., papillary type II or high-grade clear cell renal cell carcinoma (ccRCC)]. Even among various subtypes, kidney cancers are genetically diverse with variable prognoses and treatment response rates. Therefore, the key to proper treatment is the differentiation of these subtypes. Currently, a wide array of diagnostic, prognostic, and predictive biomarkers exist that may help guide the individualized care of kidney cancer patients. This review will discuss the various serum, urine, imaging, and immunohistological biomarkers available in practice.

Original languageEnglish (US)
Pages (from-to)620-632
Number of pages13
JournalTranslational Cancer Research
Issue number3
StatePublished - Jun 1 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


  • Imaging biomarker
  • Immunohistochemistry
  • Kidney cancer
  • Liquid biopsy
  • Molecular biomarker
  • Radiomics
  • Renal cell carcinoma (RCC)
  • Serum biomarker
  • Tissue biomarker
  • Urine biomarker

Fingerprint Dive into the research topics of 'Renal cell carcinoma: The search for a reliable biomarker'. Together they form a unique fingerprint.

  • Cite this

    Farber, N. J., Kim, C. J., Modi, P. K., Hon, J. D., Sadimin, E. T., & Singer, E. (2017). Renal cell carcinoma: The search for a reliable biomarker. Translational Cancer Research, 6(3), 620-632.